Open AccessNeutrophil Recovery in Breast Cancer Patients Receiving Docetaxel-Containing Chemotherapy with and without Granulocyte Colony-Stimulating Factor Prophylaxis
Author(s) -
Maureen J.B. Aarts,
Birgit E. P. J. Vriens,
Maaike de Boer,
F. P. J. Peters,
Caroline Mandigers,
M. Wouter Dercksen,
Jacqueline Stouthard,
Jolien Tol,
Laurence Jc van Warmerdam,
Agnès J. van de Wouw,
Esther Jacobs,
Carin C.D. van der Rijt,
Tineke J. Smilde,
Annette W. van der Velden,
Nelly Peer,
Vivianne C. G. TjanHeijnen
Publication year - 2017
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000479067
Subject(s) - docetaxel , medicine , granulocyte colony stimulating factor , chemotherapy , granulocyte , breast cancer , oncology , mammary gland , cancer , immunology
The primary outcome of the current study is, whether there is a protective effect of prior chemotherapy or of prior granulocyte colony-stimulating factor (G-CSF) on the next cycle blood cell counts.